ArticleJournal of virology2010
Characterization of a single-cycle rabies virus-based vaccine vector.
Article in Journal of virology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 45 citations in OpenAlex.
- Commentary: Inactivated rabies virus vectored MERS-Coronavirus vaccine induces protective immunity in mice, camels, and alpacas.Frontiers in immunology · 2025Article
- Rabies virus as vector for development of vaccine: pros and cons.Frontiers in veterinary science · 2024Article
- Third-generation rabies viral vectors allow nontoxic retrograde targeting of projection neurons with greatly increased efficiency.Cell reports methods · 2023Article
- Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model.PLoS pathogens · 2021Article
- Development and Applications of Viral Vectored Vaccines to Combat Zoonotic and Emerging Public Health Threats.Vaccines · 2020Review
- Lyssavirus Vaccine with a Chimeric Glycoprotein Protects across Phylogroups.Cell reports · 2020Article
- Identification and Characterization of a Small-Molecule Rabies Virus Entry Inhibitor.Journal of virology · 2020Article
- Vaccination with a Single-Cycle Respiratory Syncytial Virus Is Immunogenic and Protective in Mice.Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- Virus stamping for targeted single-cell infection in vitro and in vivo.Nature biotechnology · 2018Article
- Combining confocal and atomic force microscopy to quantify single-virus binding to mammalian cell surfaces.Nature protocols · 2017Article
- Viral and Synthetic RNA Vector Technologies and Applications.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Review
- Reverse Genetics Approaches to Control Arenavirus.Methods in molecular biology (Clifton, N.J.) · 2016Article
- Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics.Virology · 2015Review
- Controlled viral glycoprotein expression as a safety feature in a bivalent rabies-ebola vaccine.Virus research · 2015Article
- Rhabdovirus-based vaccine platforms against henipaviruses.Journal of virology · 2015Article
- An anterograde rabies virus vector for high-resolution large-scale reconstruction of 3D neuron morphology.Brain structure & function · 2015Article
- Induction of CD8 T cell heterologous protection by a single dose of single-cycle infectious influenza virus.Journal of virology · 2014Article
- Small-molecule probes targeting the viral PPxY-host Nedd4 interface block egress of a broad range of RNA viruses.Journal of virology · 2014Article
- Axonal and subcellular labelling using modified rabies viral vectors.Nature communications · 2013Article
- Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Recombinant rabies virus (RV)-based vectors have demonstrated their efficacy in generating long-term, antigen-specific immune responses in murine and monkey models. However, replication-competent viral vectors pose significant safety concerns due to vector pathogenicity. RV pathogenicity is largely attributed to its glycoprotein (RV-G), which facilitates the attachment and entry of RV into host cells. We have developed a live, single-cycle RV by deletion of the G gene from an RV vaccine vector expressing HIV-1 Gag (SPBN-DeltaG-Gag). Passage of SPBN-DeltaG-Gag on cells stably expressing RV-G allowed efficient propagation of the G-deleted RV. The in vivo immunogenicity data comparing single-cycle RV to a replication-competent control (BNSP-Gag) showed lower RV-specific antibodies; however, the overall isotype profiles (IgG2a/IgG1) were similar for the two vaccine vectors. Despite this difference, mice immunized with SPBN-DeltaG-Gag and BNSP-Gag mounted similar levels of Gag-specific CD8(+) T-cell responses as measured by major histocompatibility complex class I Gag-tetramer staining, gamma interferon-enzyme-linked immunospot assay, and cytotoxic T-cell assay. Moreover, these cellular responses were maintained equally at immunization titers as low as 10(3) focus-forming units for both RV vaccine vectors. CD8(+) T-cell responses were significantly enhanced by a boost with a single-cycle RV complemented with a heterologous vesicular stomatitis virus glycoprotein. These findings demonstrate that single-cycle RV is an effective alternative to replication-competent RV vectors for future development of vaccines for HIV-1 and other infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.